A device is being hailed as a breakthrough for food processing and human absorption (The Voltec Fluidic Device). It could be a game changer for Amrn. I sent IR the article:

"The discovery is the latest in a growing number of breakthroughs across the globe using the Vortex Fluidic Device (VFD).

Invented by Professor Colin Raston and his team at Flinders University in South Australia, the VFD has been hailed a game-changer for applications across the sciences due to its ability to develop a range of novel nano materials without the use of hash or toxic chemicals in the manufacturing process.

Applications have ranged from protein folding, graphene production, biofuel conversion, slicing carbon nanotubes and drug delivery.

Flinders Institute for NanoScale Science and Technology researcher Nikita Joseph said the most recent trial to enhance fish oil processing had opened new possibilities for the device.

"Using the Vortex Fluidic Device can encapsulate fish oil with a simpler process than is conventionally used," Joseph said.

"There is a possibility to produce smaller particles through this method, which may enhance people's absorption of the fish oil.

"Through this processing, we aim to improve the n omega-3 fatty acids from fish oil. This is important in processing new formulations for the food industry with improved health benefits."

The researchers found that the VFD can simplify water-in-oil-in-water encapsulation into one process, allowing scientists to exercise control over the particle size.

They also found that by altering the rotational speed, tilt angle, concentrations and ratio of components, temperature and flow rates of the VFD, they were able to vary their choice of phospholipids and combinations, changing the nature of the fish oil.

Professor Raston said the small particle fish oil was only one example of the potential VFDs offered.

"We have only scratched the surface about what is possible for this device," he said.

In 2015, the South Australian university researchers were awarded an Ig Nobel Award for creating the VFD and using it to unboil an egg.

There are now 30 VFDs across the globe with more being manufactured by 2-D Fluidics Pty Ltd, a company owned equally by Flinders University and First Graphene.

While the device is being used in countries including the UK and China for food processing, nutraceuticals, cosmetics and pharmaceuticals, Professor Raston said he would particularly like to see VFDs used to target drug delivery and reduce the side effects of medications.

"I'm very passionate about that because… (it's) not only reducing side effects, or even eliminating side effects, but most drugs that we take end up in sewage because the body only uses a small amount," he said.

"For every kilogram of drug that you buy over the counter you've got to imagine there's half a ton of waste sitting on the planet somewhere that went into making it.

"And so working out ways of making the drug molecules themselves without generating the waste is also a big ticket item for the VFD."

https://phys-org.cdn.ampproject.org/v/s/phys.org/news/2019-05-egg-unboiling-machine-fish-oil.amp?amp_js_v=a2&_gsa=1#referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fphys.org%2Fnews%2F2019-05-egg-unboiling-machine-fish-oil.html

ILT

Mateo., click on the "about us section" here is some of the verbiage:

___________________________________________________________________

"While on faculty at Harvard Medical School, Dr. Locke formulated the first 90% high concentrate formula of pure omega-3, creating the first pharmaceutical grade high quality omega-3 supplement. Dr. Locke’s goal in creating OmegaBrite was simply to create the highest purity Omega 3 supplement based on science.

We were told what we wanted to create was too impractical, too expensive to make, too difficult to distill to such a high purity, high quality omega-3. But we stuck to our goal of creating the best omega-3 possible and brought to the world OmegaBrite, high concentrate, high EPA omega-3 with no after taste.

Our commitment to purity, safety and efficacy is the foundation of everything we do. We set the standard in omega-3 to bring you the very best from science and nature."

_________________________________________________________________

They claim to be 90% Pure Pharmagrade EPA. The statement is by definition Patent Infringement.

ILT

Another Patent Infringing DS company...www.omegabrite.com

I just sent Amarin IR their website address.

Jeeez,
ILT

JL, for your interest: https://www.colorectalcancercanada.com/how-aspirin-and-omega-3-may-reduce-cancer-risk/

ILT

JL, I'm sure you're aware of the findings over poor Chinese quality control in some drugs the FDA has uncovered. That was another consideration for looking at U.S. based products. Just an FYI.

ILT

Thanks again.

ILT

JL, I found a brand that's been around since 1972, Nature's Sunshine that produces Hydrangea 100 650 mg capsules bottles sold by Iserve for a very reasonable price. If you don't mind, I'd like to know your thoughts on daily dosage?

https://www.amazon.com/Natures-Sunshine-Hydrangea-100/dp/B000WQAR6O/ref=pd_sbs_121_1/139-5001209-6775060?_encoding=UTF8&pd_rd_i=B000WQAR6O&pd_rd_r=cf9dcdff-7c0f-11e9-b98b-a55320510026&pd_rd_w=RZxsH&pd_rd_wg=2fzXp&pf_rd_p=588939de-d3f8-42f1-a3d8-d556eae5797d&pf_rd_r=CYJHA0XY7YXMBAHDX7B4&psc=1&refRID=CYJHA0XY7YXMBAHDX7B4

I was also wondering if aspirin was part of your regimen?

Thank you,
ILT

Great! Will do.

ILT

JL, would you mind sharing which site you bought from?

Thank you,
ILT

Mass., I'll be taking it, so I'll let you know. That is, if I'm still around lol.

ILT

JL, understood. Thanks for helping my understanding! My next step will be to order some as well. I'm a walking science experiment within reasonable boundaries:)

ILT

Zum., the study appears to go against the poster here who had claimed that Statins cause dementia, and didn't believe the benefits from Statins outweighed their risk.

ILT

JL, you're right I did find it confusing:( So if there is a reduction or absence of Proline, there is an anti-inflammatory effect, just as having high levels of Proline increases systemic inflammation. I'm trying to understand how the Chinese root works on the AAR Pathway. Does it have the effect of reducing Proline?

Thanks,
ILT

JL, very interesting. Thanks for sharing.

ILT

Bfost, I started by saying that Amarin reps basically suck. My brother needn't provide me with any further understanding, I get it. So, if I'm managing this second rate force, I'm ecstatic if the reps manage their time going after higher volume targets. I'm being pragmatic.

ILT

Here's another observation on Reduce-it's outcome data: How often do mounds of data pointing to further benefits come out so often as we've seen with this trial? Often we learn of trials reporting statistical significance, but nothing close to what we're learning with Reduce-it. We'll get Priority Review sooner than we think IMO.

ILT

Babr, I haven't heard good things about Amarin reps, but that's beside the point. I have to agree with Kiwi on this one. Sales live and die by the numbers. At this juncture, it's all hands on deck, and reps have no business visiting Pulmonary Docs over their target specialities.

ILT

Mateo., We'll receive priority review because:

- Reduce-it outcome data was overwhelming.

- Guidelines have added V.

- Safety profile is as good as it gets.

- The unmet need is at epidemic proportions.

IMO,
ILT

BB, if I may suggest your fortitude would be better directed at pushing regulators to ban Lovaza just like the EMA did. In the absence of L and GL, think about our script numbers then until expedited review is granted.

ILT

Chris 2125, I believe the ITC concern is way overplayed, after all, the Reduce-it population looks to medical professionals for treatment. You'll always have the DIY or noncompliant population choosing not to see doctors. HOWEVER, over time, we'll see these reluctant at risk groups crossover, as Vascepa becomes more pervasive in the consciousness of consumers by osmosis.

ILT

MNBio., there's research to suggest Metformin can be used as an anti-aging drug to extend life.

ILT

sts66, it's unfortunate for consumers who get hurt the most. We've all learned from Dr. Preston's research that OTC fish oils do far more harm than good.

ILT

Exwannabe, thx for the feedback.

ILT

Extremist., I agree that it provides further validation. Are you saying that it would be permissible that a knock-off be sold in India, but wouldn't be in countries outside of India? If yes, patents are filed Internationally, and would set a bad precedent to sit idle.

ILT

Kiwi, IMO, court dates are made so far ahead, that it brings in to question if litigation encourages rather than deter the behavior?

ILT

Cardio, I'm on Vascepa since 2013, not because I'm at risk, but rather for overall wellness (off-label). I'm certain if I asked my brother if I should go with 2gms, he would say Reduce-it trial showed benefits at 4gms period.

ILT

Raf, I've so often heard from reliable sources how bad many doctors are, I certainly wouldn't think twice to be surprised here. Unfortunately, they're not all cut from the same cloth, and unfortunately, a degree is meaningless to go by.

ILT

Extremist.., on it's face, isn't APCEDEN infringing on NWBO patents? If not, then it would compete with DCVax no? Unless India's drug approval process is lax, approval of APCEDEN would indicate it's effects have shown benefits. Wouldn't having a direct competitor be an issue?

ILT

Circuit.. decoupling Statins from V would mean throwing practice changing Reduce-it results out the window.

ILT

Keystone., IMO, V needs no further derisking as consideration towards valuation.

-Let's not overlook the high-risk burdon for BP's to bring new drugs to market. We know the astronomical cost and years it takes has trended heavily in favor of research going overseas. Not to mention, only a small percentage pass trial towards FDA consideration.

-Drugs have the inherent risk of side effects which could see a large unexpected lawsuit wipe a drug out permanently.

-Besides Vascepa being "holistic", the body can't live without EPA. It's worth noting, that 35% of all my brother's new patients come in already taking an OTC fish Oil. This data is something that you can pretty much generalize across the board nationally.

-Louise Chen of C.Fitzgerald sees Vascepa Branded OTC annual sales of $500 million/year beyond 2029.

At the rate of new data releases, the list above IMO is conservative.

ILT

Keystone., agreed, would love such a catalyst to set a floor at that price.

ILT

MNBio., you're right, I didn't consider Amarin's book value through a financial prism. When Lovaza was BO, it was a single drug company with a relatively small treatment population. I'm looking at 1 in 4 U.S adults fit the Reduce-trial population. Worldwide we're looking at 10's of millions of people that would benefit from V. Anyway you look at it, with a market that "enormous", yes $31 BO offer is a joke.

JMHO,

ILT

Keystone., thanks for sharing with us! As to a BP offer of $35, IMO, that's way too light, especially for the fact that failing Lovaza was BO for $31.

ILT

Bfost great post!

ILT

Exactly, and if the worst of it is that I need to be patient, so be it. While we wait for our investment to explode, think of those who chose the wrong horse. We have Secretariat!

ILT

CBB,

There's no question that BP would do a better job and also, they must be salivating for Amarin, particularly those BP's that are an ideal fit with an apparatus to catapult V. For years I've heard the drumbeat that "private practice" is quickly becoming a dinosaur. Recently, I've come to realize that the train has already left the station. Take the Bronx for example, where my brother practices medicine. Montefiore Medical has been methodically swallowing up private practices, luring away the few independent physician holdouts, while buying up more and more properties and expanding its footprint. A generation ago or so, working at a hospital meant not making a high salary, but rather earning a living by physician standards. I was surprised to see recently published average salaries for specialties paid by hospitals. There's no incentive to be in private practice. Since reps are not allowed to solicit hospitals, just how do Doctors keep up to date? I contend that they're not waiting around to find out, but rather most, if not all, are using their mobile devices. When my Dad was hospitalized last year, I noticed that all the Doctors I saw had their faces fixed on their phones.

My brother has been quite active giving talks on diabetes lately. He said that Doctors have inadequate knowledge of the best treatments. It's so bad as he put it, that he said: "they should go back to med school for more training." IMHO, SOC designation caters to doctors in a way that is designed for the newer generation to embrace.

Finally, when Amrn gets FDA approval, Amarin will be free to bombard the market with advertising in a way I believe will crush any concern over sales force size.

ILT

Marki..,

I don't underestimate BP's resources to catepult sales in contrast to a small Amarin sales force. However, find me a precedent of a drug that became SOC for the ADA before approval, soon to become the same for the AHA/ACC for an unmet need, for the number one cause of death in the world, and finally, in a digital world everyone communicates in today. Vascepa will fly despite what you believe imho.

ILT

I think WS is conditioned to believe that high ticket complex drugs ought to trade high, and not relatively inexpensive natural ones. The market is still struggling to understand the distinction between fish oil and Icosapent Ethyl. Once that threshold is passed in understanding, all bets are on imo.

ILT

Imagine, we haven't seen nothing yet:)

mrmain..,

I'm certain your prayers will be answered much sooner than you think. We haven't seen papers at such scale released in succession, each shedding new light on the benefits of Icosapent Ethyl. The benefits to society is so enormous, that Vascepa won't be able to get out of it's own way. It's a once in a lifetime opportunity in this investment space. You won't find a better return elsewhere in the long run.

ILT